Keywords: novartis, b-ms, withdraw, zelmac, application, europe, partner
Novartis and B-MS withdraw Zelmac application in Europe
Article | 07 June 2001
Novartis and partner Bristol-Myers Squibb have suffered a setback withthe withdrawal of their marketing application for Zelmac (tegaserod), a 5-HT4 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
